Samsung Seeks To Scrub US Soliris Patents With A Pair Of USPTO Challenges

Small Pool Of Eculizumab Biosimilar Developers Includes Settler Amgen

 
• By Dean Rudge

Samsung Bioepis has taken to five its number of IPR challenges to Alexion’s US Soliris intellectual property portfolio, filing two simultaneously.

Macro photo of tooth wheel mechanism with PATENTS concept letters
• Source: Shutterstock

More from Biosimilars

More from Products